Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology

Bhattacharyya S, Fusar-Poli P, Borgwardt S, Martin-Santos R, Nosarti C, O’Carroll C et al (2009). Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry 66: 442–451.

Borgwardt SJ, Allen P, Bhattacharyya S, Fusar-Poli P, Crippa JA, Seal ML et al (2008). Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiatry 64: 966–973.

Breiter HC, Etcoff NL, Whalen PJ, Kennedy WA, Rauch SL, Buckner RL et al (1996). Response and habituation of the human amygdala during visual processing of facial expression. Neuron 17: 875–887.

Bullmore E, Long C, Suckling J, Fadili J, Calvert G, Zelaya F et al (2001). Colored noise and computational inference in neurophysiological (fMRI) time series analysis: resampling methods in time and wavelet domains. Hum Brain Mapp 12: 61–78.

Cabeza R, St Jacques P (2007). Functional neuroimaging of autobiographical memory. Trends Cogn Sci 11: 219–227.

Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L et al (2004). Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 29: 417–426.

Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB (1976). Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. Clin Pharmacol Ther 19: 300–309.

Doeller CF, King JA, Burgess N (2008). Parallel striatal and hippocampal systems for landmarks and boundaries in spatial memory. Proc Natl Acad Sci USA 105: 5915–5920.

D’Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT et al (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29: 1558–1572.

D’Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G et al (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 57: 594–608.

D’Souza DC, Braley G, Blaise R, Vendetti M, Oliver S, Pittman B et al (2008). Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans. Psychopharmacology (Berl) 198: 587–603.

Elphick MR, Egertova M (2001). The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond B Biol Sci 356: 381–408.

Fadda P, Robinson L, Fratta W, Pertwee RG, Riedel G (2004). Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats. Neuropharmacology 47: 1170–1179.

Fleck MS, Daselaar SM, Dobbins IG, Cabeza R (2006). Role of prefrontal and anterior cingulate regions in decision-making processes shared by memory and nonmemory tasks. Cereb Cortex 16: 1623–1630.

Folstein MF, Luria R (1973). Reliability, validity, and clinical application of the Visual Analogue Mood Scale. Psychol Med 3: 479–486.

Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R et al (2009). Distinct effects of Δ9-tetrahydrocannabinol and cannabidiol on neural acti. Arch Gen Psychiatry 66: 95–105.

Hall W, Solowij N (1998). Adverse effects of cannabis. Lancet 352: 1611–1616.

Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998). Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 95: 8268–8273.

Haxby JV, Grady CL, Horwitz B, Ungerleider LG, Mishkin M, Carson RE et al (1991). Dissociation of object and spatial visual processing pathways in human extrastriate cortex. Proc Natl Acad Sci USA 88: 1621–1625.

Ilan AB, Gevins A, Coleman M, ElSohly MA, de Wit H (2005). Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. Behav Pharmacol 16: 487–496.

Karniol IG, Carlini EA (1973). Pharmacological interaction between cannabidiol and delta 9-tetrahydrocannabinol. Psychopharmacologia 33: 53–70.

Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA (1974). Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man. Eur J Pharmacol 28: 172–177.

Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261–276.

Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernandez-Ruiz J (2005). Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis 19: 96–107.

Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561–564.

McDonald J, Schleifer L, Richards JB, de Wit H (2003). Effects of THC on behavioral measures of impulsivity in humans. Neuropsychopharmacology 28: 1356–1365.

McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G et al (1992). The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat 9: 199–213.

Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO (2007). Cannabidiol—recent advances. Chem Biodivers 4: 1678–1692.

Mechoulam R, Spatz M, Shohami E (2002). Endocannabinoids and neuroprotection. Sci STKE 2002: RE5.

Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M et al (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370: 319–328.

Morgan CJ, Curran HV (2008). Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 192: 306–307.

Morris JS, Frith CD, Perrett DI, Rowland D, Young AW, Calder AJ et al (1996). A differential neural response in the human amygdala to fearful and happy facial expressions. Nature 383: 812–815.

Nelson HE (1982). National Adult Reading Test (NART): Test Manual. NFER-Nelson: Windsor.

O’Leary DS, Block RI, Koeppel JA, Flaum M, Schultz SK, Andreasen NC et al (2002). Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology 26: 802–816.

Pertwee RG (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153: 199–215.

Phan KL, Angstadt M, Golden J, Onyewuenyi I, Popovska A, de Wit H (2008). Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. J Neurosci 28: 2313–2319.

Potter DJ, Clark P, Brown MB (2008) Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci 53: 90–94

Price CJ, Wise RJ, Warburton EA, Moore CJ, Howard D, Patterson K et al (1996). Hearing and saying. The functional neuro-anatomy of auditory word processing. Brain 119 (Pt 3): 919–931.

Ramaekers JG, Moeller MR, van Ruitenbeek P, Theunissen EL, Schneider E, Kauert G (2006). Cognition and motor control as a function of Delta9-THC concentration in serum and oral fluid: limits of impairment. Drug Alcohol Depend 85: 114–122.

Rubia K, Russell T, Overmeyer S, Brammer MJ, Bullmore ET, Sharma T et al (2001). Mapping motor inhibition: conjunctive brain activations across different versions of go/no-go and stop tasks. Neuroimage 13: 250–261.

Sarne Y, Mechoulam R (2005). Cannabinoids: between neuroprotection and neurotoxicity. Curr Drug Targets CNS Neurol Disord 4: 677–684.

Simons JS, Gilbert SJ, Owen AM, Fletcher PC, Burgess PW (2005). Distinct roles for lateral and medial anterior prefrontal cortex in contextual recollection. J Neurophysiol 94: 813–820.

Spielberger C (1983). Manual of the State-Trait Anxiety Inventory. Consulting Psychologists Press Inc: Palo Alto, CA.

Talairach J, Tournoux P (1988). Co-planar Stereotaxic Atlas of the Human Brain. Thieme Medical: New York.

Tart CT (1970). Marijuana intoxication common experiences. Nature 226: 701–704.

Viveros MP, Llorente R, Moreno E, Marco EM (2005). Behavioural and neuroendocrine effects of cannabinoids in critical developmental periods. Behav Pharmacol 16: 353–362.

Zuardi AW (2008). Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 30: 271–280.

Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS (1993). Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 7: 82–88.

Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982). Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 76: 245–250.

Zuardi AW, Hallak JE, Dursun SM, Morais SL, Sanches RF, Musty RE et al (2006). Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol 20: 683–686.